4:41 PM ET
10-Q
Financial Results
Telomir Pharmaceuticals Q3 2026 Results: Net Loss of $705K, Loss Narrows
Telomir Pharmaceuticals reported a net loss of $3.42 million for the nine months ended September 30, 2026, a significant improvement from the $8.35 million loss in the prior year period. However, the net loss attributable to common stockholders surged to $49.53 million due to a $46.11 million deemed dividend, while cash reserves decreased to $4.52 million from $7.29 million at year-end 2025.
- Key figure
- Net loss $705K